Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
LucidWargames
QuickAnswers
LucidSearch
BioPharma and Tech News

Contact Us

Search

Skin cancer

Public_Health

Latest Public Health News - Sept 11th to Sept 25

Watch Our Video Summary Capturing Top Public Health News from the Last Two…

EADV 2025_Preview_by_LucidQuest

EADV 2025 Preview: Dermatology and Venereology Highlights to Watch

EADV 2025 at a Glance Ahead of EADV 2025, LucidQuest highlights…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Rare Disease News
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: Transcenta x EirGenix HiCB licensing
Public Health 2025 Review: Prevention Under Pressure and Signals Too Loud to Ignore
Lucid Diligence Brief: DP Technology Series C for AI-for-Science initiative
Cardiovascular 2025 Review: From late rescue to earlier, smarter intervention
Rare Disease 2025 Preview: From Orphan Innovation to a System-Level Stress Test

Tags

Asundexian Autoimmune disease therapies BIA brain tumors BRCA mutation status Brenzavvy CAD cancer cancer neuroscience Cereno Scientific Charcot Marie Tooth disease type 2S Chiesi Rare Diseases Clinical immunology continuous bioprocessing Echocardiography monitoring Elranatamab evinova FDA gene therapy approvals FDA obesity approvals Gene and cell therapy in hematology hair loss treatments Headache disorders Health Systems Transformation hematology international atherosclerosis society investor brief licensing deal Mild cognitive impairment Navigator Medicines Neoantigen vaccine NMDA NMPA China non viral vectors Pancreatic ductal adenocarcinoma pharma pharmacogenomics pneumonia Rare disease drug pipeline screening Sema4 Shanghai Mental Health Center SKYRIZI Toripalimab urticaria Women’s health market trends

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: Transcenta x EirGenix HiCB licensing
Public Health 2025 Review: Prevention Under Pressure and Signals Too Loud to Ignore
Lucid Diligence Brief: DP Technology Series C for AI-for-Science initiative
Cardiovascular 2025 Review: From late rescue to earlier, smarter intervention
Rare Disease 2025 Preview: From Orphan Innovation to a System-Level Stress Test

TAGS

Asundexian Autoimmune disease therapies BIA brain tumors BRCA mutation status Brenzavvy CAD cancer cancer neuroscience Cereno Scientific Charcot Marie Tooth disease type 2S Chiesi Rare Diseases Clinical immunology continuous bioprocessing Echocardiography monitoring Elranatamab evinova FDA gene therapy approvals FDA obesity approvals Gene and cell therapy in hematology hair loss treatments Headache disorders Health Systems Transformation hematology international atherosclerosis society investor brief licensing deal Mild cognitive impairment Navigator Medicines Neoantigen vaccine NMDA NMPA China non viral vectors Pancreatic ductal adenocarcinoma pharma pharmacogenomics pneumonia Rare disease drug pipeline screening Sema4 Shanghai Mental Health Center SKYRIZI Toripalimab urticaria Women’s health market trends

Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
LucidWargames
QuickAnswers
LucidSearch
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy